Multipark

Faculty of Medicine | Lund University

Menu

MultiPark

MOVING SCIENCE FORWARD

MultiPark is a strategic research area funded by the Swedish Government. Building on the strong tradition of cutting-edge research on Parkinson's and Alzheimer's diseases at Lund University, our vision is to create new and innovative strategies for improved and novel treatments, disease modifications and eventually cures for neurodegenerative diseases, in order to improve the quality of life for people living and ageing with these disorders.

News

On September 7th, the patient organisation Parkinson Skåne is invited to a half-day study visit at the Biomedical Center (BMC). The event will consist of a series of short presentations, followed by guided tours to several research labs at BMC.

Researchers at Lund University have used a completely new preclinical technique and analysis of tissue from patients to show exactly what happens when certain patients with Parkinson’s disease are restored as a result of nerve cell transplants. They have also identified what makes many of the transplant patients develop serious side effects in the form of involuntary movements.

In the late 1980s and over the 1990s, researchers at Lund University in Sweden pioneered the transplantation of new nerve cells into the brains of patients with Parkinson’s disease. The outcomes proved for the first time that transplanted nerve cells can survive and function in the diseased human brain. Some patients showed marked improvement after the transplantation while others showed moderate or no relief of symptoms. A small number of patients suffered unwanted side-effects in the form of involuntary movements.

The project, that started 17 years ago at a phone conference between Glostrup, Denmark and San Diego, USA, has delivered. On the 29th of April, the U.S. Food and Drug Administration (FDA) approved ACADIA Pharmaceuticals’ NUPLAZID™ (pimavanserin), the first drug approved for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. NUPLAZID is a non-dopaminergic, selective serotonin inverse agonist preferentially targeting 5-HT2A receptors.

On April 11th, MultiPark and BAGADILICO organized, together with Parkinson Skåne and Studieförbundet Vuxenskolan a half-day event for the public in the Skåne University Hospital´s main auditorium. The host of the day was Johan Wester, known from the comedy program "HippHipp!", who guided the audience through this year´s theme - 'How you can affect and improve your everyday life when living with Parkinson´s disease’. 

multipark logga orginal

Contact

For more information, please contact:

Jens Persson, Public Relations Officer
 +46 46 222 08 76
 jens.persson@med.lu.se 

Site overview